DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Samantha Semenkow - 1 Semenkow - 1
Top related locs:
hematology
Top related orgs:
Prime Medicine - 1 Citi - 1 and Drug Administration - 1 Cambridge - 1 Research - 1

Search resuls for: "Prime Medicine"


7 mentions found


☆ Shares of this gene editing company are due to surge more than 45%, Citi says
  + stars: | 2024-05-16 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
After a period of steady underperformance, investors should pick up shares of biotech Prime Medicine as regains the market's favor, according to Citi. Analyst Samantha Semenkow upgraded the preclinical-stage company to buy from neutral and kept her price target of $10 per share, which implies 47.9% potential upside from the stock's latest close. To be sure, Semenkow said she remains cautious on Prime's cash position and expects the Cambridge-based company to need to raise again in the next 12 to 18 months. Ongoing [business development] efforts could provide a source of non-dilutive cash and potential upside to her target price, she added. The company also had significantly more cash and cash equivalents on hand at the end of the previous quarter compared to the end of last year.
Persons: Samantha Semenkow, Semenkow Organizations: Prime Medicine, Citi, and Drug Administration, Cambridge, Research Locations: hematology
☆ 'Compelling' and 'attractive': These stocks are firing on all cylinders, JPMorgan says
  + stars: | 2022-11-19 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
Analysts at JPMorgan said this week there's a whole host of stocks that they say are flying under the radar. CNBC Pro combed through top JPMorgan research to find some unique stocks that are just too compelling to ignore. At the same time, Allstate's low stock valuation is "compelling," with a "depressed multiple on depressed earnings." With visibility improving, now's the time to buy the stock, JPMorgan concluded. ... .Our positive view reflects an expected recovery in margins & ALL's compelling valuation.
☆ This gene-editing company that went public last month could rally 20%, Jefferies says
  + stars: | 2022-11-14 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Prime Medicine shares could pop the company works toward a gene therapy that could address nine out of every 10 genetic mutations, Jefferies said Monday. The company went public Oct. 20 through an initial public offering. "PRME believes that key advantages of Prime Editing technology lie in its versatility, precision, effectiveness and breadth." Yang said Prime Medicine has a unique focus on search-and-replace genome editing, which can theoretically use one-time therapies to address 90% of the approximately 75,000 known genetic mutations. Search-and-replace can do more gene conversions without off-target editing or breaking double-strands of DNA, which allows it to have broader impact, Yang said.
☆ Biotech firm Prime Medicine valued at $1.8 bln in strong debut
  + stars: | 2022-10-20 | by ( ) www.reuters.com   time to read: +2 min
Oct 20 (Reuters) - Biotechnology firm Prime Medicine (PRME.O) notched a valuation of about $1.8 billion in its Nasdaq debut on Thursday, braving tough market conditions that have forced several IPO-bound companies to slam the breaks on their listing plans. Shares of Prime Medicine started trading nearly 12% above their IPO price of $17 each. Its investors include Alphabet Inc's (GOOGL.O) GV, Newpath Partners, Moore Strategic Ventures and Samsara Biocapital, the firm's website showed. Prime Medicine sold 10.3 million shares in its upsized offering, raising $175 million in proceeds priced at $17 apiece, the midpoint of its proposed range of $16 and $18 per share. Register now for FREE unlimited access to Reuters.com RegisterReporting by Manya Saini in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.
☆ Prime Medicine dipped 10% in its public debut. We dug through the biotech's 283-page filing to find 5 key takeaways about the company's plan to commercialize gene editing.
  + stars: | 2022-10-20 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +8 min
The gene-editing biotech Prime Medicine went public on Thursday. From a key patent to an uncertain timeline, here are five takeaways from Prime's filing. Its goal is to advance prime editing, a twist on CRISPR gene editing that could allow for a wider range of edits to DNA. Prime editing, another version of next-generation gene editing, works like a word processor, "searching for the correct location and replacing or repairing a wide variety of target DNA," the filing said. Jessica Rinaldi/The Boston Globe via Getty ImagesDavid Liu, a Harvard gene-editing scientist who co-invented base editing and prime editing, is Prime's largest shareholder.
☆ Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn
  + stars: | 2022-10-12 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +8 min
CRISPR companies are faring better by producing faster and more dramatic clinical results. A layoff tracker from Fierce Biotech counts at least 90 drug companies that have laid off staff in 2022. Gene-editing biotechs have avoided the brunt of the downturn because of fast clinical successIntellia Therapeutics is developing CRISPR-based gene-editing medicines that could cure diseases. Just in the past month, CRISPR Therapeutics moved into a swanky new headquarters in Boston that can house up to 1,000 people. BeamTo be sure, 2022 hasn't been smooth sailing for the CRISPR companies.
☆ Prime Medicine is gearing up for a $200 million IPO. We dug through the biotech's 282-page filing to find 5 key takeaways about the company's plan to commercialize gene editing.
  + stars: | 2022-09-28 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +8 min
From an uncertain timeline to the clinic to a key patent, here are 5 takeaways from Prime's filing. The company's goal is to advance prime editing, a twist on CRISPR gene editing that could allow for a wider range of edits to DNA. Prime editing is another version of next-generation gene editing. Prime's filing comes in a difficult market for biotechs, but particularly for companies that have yet to start human testing. Jessica Rinaldi/The Boston Globe via Getty ImagesDavid Liu, a Harvard gene-editing scientist who co-invented base editing and prime editing, is currently Prime's largest shareholder.
0 next >>
Total: 7